Importance of Drug Transporters in Pharmacokinetics and Drug Safety

REFERENCES

• Allen J. D., Brinkhuis R. F., Wijnholds J., Schinkel A. H. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res. 1999; 59: 4237–4241
   PubMed Web of Science ®Google Scholar
• Anzai N., Kanai Y., Endou H. Organic anion transporter family: current knowledge. J. Pharmacol. Sci. 2006; 100: 411–426
   PubMed Web of Science ®Google Scholar
• Backman J. T., Kyrklund C., Neuvonen M., Neuvonen P. J. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther. 2002; 72: 685–691
   PubMed Web of Science ®Google Scholar
• Badagnani I., Castro R. A., Taylor T. R., Brett C. M., Huang C. C., Stryke D., Kawamoto M., Johns S. J., Ferrin T. E., Carlson E. J., Burchard E. G., Giacomini K. M. Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J. Pharmacol. Exp. Ther. 2006; 318: 521–529
   PubMed Web of Science ®Google Scholar
• Barendt W. M., Wright S. H. The human organic cation transporter (hOCT2) recognizes the degree of substrate ionization. J. Biol. Chem. 2002; 277: 22491–22496
   PubMed Web of Science ®Google Scholar
• Beringer P. M., Slaughter R. L. Transporters and their impact on drug disposition. Ann. Pharmacother. 2005; 39: 1097–1108
   PubMed Web of Science ®Google Scholar
• Bourdet D. L., Pritchard J. B., Thakker D. R. Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J. Pharmacol. Exp. Ther. 2005; 315: 1288–1297
   PubMed Web of Science ®Google Scholar
• Breedveld P., Zelcer N., Pluim D., Sonmezer O., Tibben M. M., Beijnen J. H., Schinkel A. H., van Tellingen O., Borst P., Schellens J. H. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004; 64: 5804–5811
   PubMed Web of Science ®Google Scholar
• Breidert T., Spitzenberger F., Grundemann D., Schomig E. Catecholamine transport by the organic cation transporter type 1 (OCT1). Br. J. Pharmacol. 1998; 125: 218–224
   PubMed Web of Science ®Google Scholar
• Bretschneider B., Brandsch M., Neubert R. Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm. Res. 1999; 16: 55–61
   PubMed Web of Science ®Google Scholar
• Brouwers J. R., de Smet P. A. Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. Clin. Pharmacokinet. 1994; 27: 462–485
   PubMed Web of Science ®Google Scholar
• Chen A. Y., Yu C., Potmesil M., Wall M. E., Wani M. C., Liu L. F. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res. 1991; 51: 6039–6044
   PubMed Web of Science ®Google Scholar
• Chen Z. S., Kawabe T., Ono M., Aoki S., Sumizawa T., Furukawa T., Uchiumi T., Wada M., Kuwano M., Akiyama S. I. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol. Pharmacol. 1999; 56: 1219–1228
   PubMed Web of Science ®Google Scholar
• Choudhuri S., Klaassen C. D. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. 2006; 25: 231–259
   PubMed Web of Science ®Google Scholar
• Cohen S. M., Klaunig J., Meek M. E., Hill R. N., Pastoor T., Lehman-McKeeman L., Bucher J., Longfellow D. G., Seed J., Dellarco V., Fenner-Crisp P., Patton D. Evaluating the human relevance of chemically induced animal tumors. Toxicol. Sci. 2004; 78: 181–186
   PubMed Web of Science ®Google Scholar
• Conseil G., Deeley R. G., Cole S. P. Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet. Genomics 2005; 15: 523–533
   PubMed Web of Science ®Google Scholar
• Cui Y., Konig J., Buchholz J. K., Spring H., Leier I., Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 1999; 55: 929–937
   PubMed Web of Science ®Google Scholar
• Cvetkovic M., Leake B., Fromm M. F., Wilkinson G. R., Kim R. B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 1999; 27: 866–871
   PubMed Web of Science ®Google Scholar
• Deguchi T., Takemoto M., Uehara N., Lindup W. E., Suenaga A., Otagiri M. Renal clearance of endogenous hippurate correlates with expression levels of renal organic anion transporters in uremic rats. J. Pharmacol. Exp. Ther. 2005; 314: 932–938
   PubMed Web of Science ®Google Scholar
• Dixit R., Ward P. Use of Classical Pharmacokinetic Evaluations in Drug Development and Safety Assessment Toxicokinetics and Risk Assessment, J. C. Lipscomb, E. V. Ohanian. Informa Healthcare USA Inc., New York 2006; 95–122
   Google Scholar
• Dringen R., Hamprecht B., Broer S. The peptide transporter PepT2 mediates the uptake of the glutathione precursor CysGly in astroglia-rich primary cultures. J. Neurochem. 1998; 71: 388–393
   Google Scholar
• Food and Drug Administration. Drug Interaction Studies—Study Design, Data Analysis, and Implications for Dosing and Labeling 2006
   Google Scholar
• Frenia M. L., Long K. S. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann. Pharmacother. 1992; 26: 234–237
   PubMed Web of Science ®Google Scholar
• Hayer-Zillgen M., Bruss M., Bonisch H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br. J. Pharmacol. 2002; 136: 829–836
   PubMed Web of Science ®Google Scholar
• He G., Massarella J., Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 1999; 37: 471–484
   PubMed Web of Science ®Google Scholar
• He W., Miao F. J., Lin D. C., Schwandner R. T., Wang Z., Gao J., Chen J. L., Tian H., Ling L. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature 2004; 429: 188–193
   PubMed Web of Science ®Google Scholar
• Hebert M. F., Dowling A. L., Gierwatowski C., Lin Y. S., Edwards K. L., Davis C. L., Marsh C. L., Schuetz E. G., Thummel K. E. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 2003; 13: 661–674
   PubMedGoogle Scholar
• Herweijer H., Sonneveld P., Baas F., Nooter K. Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J. Natl. Cancer Inst. 1990; 82: 1133–1140
   PubMed Web of Science ®Google Scholar
• Hill G., Cihlar T., Oo C., Ho E. S., Prior K., Wiltshire H., Barrett J., Liu B., Ward P. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab. Dispos. 2002; 30: 13–19
   PubMed Web of Science ®Google Scholar
• Hirohashi T., Suzuki H., Sugiyama Y. Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J. Biol. Chem. 1999; 274: 15181–15185
   PubMed Web of Science ®Google Scholar
• Ho E. S., Lin D. C., Mendel D. B., Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J. Am. Soc. Nephrol. 2000; 11: 383–393
   PubMed Web of Science ®Google Scholar
• Ho R. H., Tirona R. G., Leake B. F., Glaeser H., Lee W., Lemke C. J., Wang Y., Kim R. B. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006; 130: 1793–1806
   PubMed Web of Science ®Google Scholar
• Horio M., Lovelace E., Pastan I., Gottesman M. M. Agents which reverse multidrug-resistance are inhibitors of [3H]vinblastine transport by isolated vesicles. Biochim. Biophys. Acta 1991; 1061: 106–110
   PubMed Web of Science ®Google Scholar
• Hosoyamada M., Sekine T., Kanai Y., Endou H. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am. J. Physiol. 1999; 276: F122–128
   PubMed Web of Science ®Google Scholar
• Huisman M. T., Smit J. W., Crommentuyn K. M., Zelcer N., Wiltshire H. R., Beijnen J. H., Schinkel A. H. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. Aids 2002; 16: 2295–2301
   PubMed Web of Science ®Google Scholar
• Inotsume N., Nishimura M., Nakano M., Fujiyama S., Sato T. The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. J. Clin. Pharmacol. 1990; 30: 50–56
   PubMed Web of Science ®Google Scholar
• Jariyawat S., Sekine T., Takeda M., Apiwattanakul N., Kanai Y., Sophasan S., Endou H. The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J. Pharmacol. Exp. Ther. 1999; 290: 672–677
   PubMed Web of Science ®Google Scholar
• Jonker J. W., Wagenaar E., van Deemter L., Gottschlich R., Bender H. M., Dasenbrock J., Schinkel A. H. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug. Br. J. Pharmacol. 1999; 127: 43–50
   PubMed Web of Science ®Google Scholar
• Juliano R. L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 1976; 455: 152–162
   PubMed Web of Science ®Google Scholar
• Kajosaari L. I., Niemi M., Neuvonen M., Laitila J., Neuvonen P. J., Backman J. T. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin. Pharmacol. Ther. 2005; 78: 388–399
   PubMed Web of Science ®Google Scholar
• Kedderis G. L. Pharmacokinetics of drug interactions. Adv. Pharmacol. 1997; 43: 189–203
   Google Scholar
• Kim R. B., Fromm M. F., Wandel C., Leake B., Wood A. J., Roden D. M., Wilkinson G. R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 1998; 101: 289–294
   PubMed Web of Science ®Google Scholar
• Kimchi-Sarfaty C., Oh J. M., Kim I. W., Sauna Z. E., Calcagno A. M., Ambudkar S. V., Gottesman M. M. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315: 525–528
   PubMed Web of Science ®Google Scholar
• Kool M., Van Der Linden M., de Haas M., Scheffer G. L., de Vree J. M., Smith A. J., Jansen G., Peters G. J., Ponne N., Scheper R. J., Elferink R. P., Baas F., Borst P. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. U S A 1999; 96: 6914–6919
   PubMed Web of Science ®Google Scholar
• Kruh G. D., Belinsky M. G. The MRP family of drug efflux pumps. Oncogene 2003; 22: 7537–7552
   PubMed Web of Science ®Google Scholar
• Lacy S. A., Hitchcock M. J., Lee W. A., Tellier P., Cundy K. C. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol. Sci. 1998; 44: 97–106
   PubMed Web of Science ®Google Scholar
• Lee C. G., Gottesman M. M., Cardarelli C. O., Ramachandra M., Jeang K. T., Ambudkar S. V., Pastan I., Dey S. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37: 3594–3601
   PubMed Web of Science ®Google Scholar
• Lee W., Glaeser H., Smith L. H., Roberts R. L., Moeckel G. W., Gervasini G., Leake B. F., Kim R. B. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J. Biol. Chem. 2005; 280: 9610–9617
   PubMed Web of Science ®Google Scholar
• Mahar Doan K. M., Humphreys J. E., Webster L. O., Wring S. A., Shampine L. J., Serabjit-Singh C. J., Adkison K. K., Polli J. W. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 2002; 303: 1029–1037
   PubMed Web of Science ®Google Scholar
• Maliepaard M., van Gastelen M. A., Tohgo A., Hausheer F. H., van Waardenburg R. C., de Jong L. A., Pluim D., Beijnen J. H., Schellens J. H. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin. Cancer Res. 2001; 7: 935–941
   PubMed Web of Science ®Google Scholar
• Markovich D., Murer H. The SLC13 gene family of sodium sulphate/carboxylate cotransporters. Pflugers Arch. 2004; 447: 594–602
   Google Scholar
• Matter K., Balda M. S. Functional analysis of tight junctions. Methods 2003; 30: 228–234
   PubMed Web of Science ®Google Scholar
• Meek M. E., Bucher J. R., Cohen S. M., Dellarco V., Hill R. N., Lehman-McKeeman L. D., Longfellow D. G., Pastoor T., Seed J., Patton D. E. A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol. 2003; 33: 591–653
   PubMed Web of Science ®Google Scholar
• Mita S., Suzuki H., Akita H., Hayashi H., Onuki R., Hofmann A. F., Sugiyama Y. Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metab. Dispos. 2006; 34: 1575–1581
   PubMed Web of Science ®Google Scholar
• Morrow C. S., Smitherman P. K., Townsend A. J. Role of multidrug-resistance protein 2 in glutathione S-transferase P1–1-mediated resistance to 4-nitroquinoline 1-oxide toxicities in HepG2 cells. Mol. Carcinog. 2000; 29: 170–178
   PubMed Web of Science ®Google Scholar
• Motohashi H., Uwai Y., Hiramoto K., Okuda M., Inui K. Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur. J. Pharmacol. 2004; 503: 25–30
   PubMed Web of Science ®Google Scholar
• Muck W., Mai I., Fritsche L., Ochmann K., Rohde G., Unger S., Johne A., Bauer S., Budde K., Roots I., Neumayer H. H., Kuhlmann J. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin. Pharmacol. Ther. 1999; 65: 251–261
   PubMed Web of Science ®Google Scholar
• Najjar T. A., Abou-Auda H. S., Ghilzai N. M. Influence of piperacillin on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate. Cancer Chemother. Pharmacol. 1998; 42: 423–428
   PubMed Web of Science ®Google Scholar
• Seithel A., Eberl S., Singer K., Auge D., Heinkele G., Wolf N. B., Dorje F., Fromm M. F., Konig J. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab. Dispos. 2007; 35: 779–786
   PubMed Web of Science ®Google Scholar
• Servais A., Lechat P., Zahr N., Urien S., Aymard G., Jaudon M. C., Deray G., Isnard Bagnis C. Tubular transporters and clearance of adefovir. Eur. J. Pharmacol. 2006; 540: 168–174
   PubMed Web of Science ®Google Scholar
• Shimizu M., Fuse K., Okudaira K., Nishigaki R., Maeda K., Kusuhara H., Sugiyama Y. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab. Dispos. 2005; 33: 1477–1481
   PubMed Web of Science ®Google Scholar
• Shitara Y., Hirano M., Sato H., Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 2004; 311: 228–236
   PubMed Web of Science ®Google Scholar
• Shitara Y., Horie T., Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci. 2006; 27: 425–446
   PubMed Web of Science ®Google Scholar
• Shitara Y., Sato H., Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol. 2005; 45: 689–723
   PubMed Web of Science ®Google Scholar
• Simonson S. G., Raza A., Martin P. D., Mitchell P. D., Jarcho J. A., Brown C. D., Windass A. S., Schneck D. W. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin. Pharmacol. Ther. 2004; 76: 167–177
   PubMed Web of Science ®Google Scholar
• Sorrentino B. P., Brandt S. J., Bodine D., Gottesman M., Pastan I., Cline A., Nienhuis A. W. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257: 99–103
   PubMed Web of Science ®Google Scholar
• Sun W., Wu R. R., van Poelje P. D., Erion M. D. Isolation of a family of organic anion transporters from human liver and kidney. Biochem. Biophys. Res. Commun. 2001; 283: 417–422
   PubMed Web of Science ®Google Scholar
• Sweet D. H., Miller D. S., Pritchard J. B., Fujiwara Y., Beier D. R., Nigam S. K. Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J. Biol. Chem. 2002; 277: 26934–26943
   PubMed Web of Science ®Google Scholar
• Tahara H., Kusuhara H., Endou H., Koepsell H., Imaoka T., Fuse E., Sugiyama Y. A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J. Pharmacol. Exp. Ther. 2005; 315: 337–345
   PubMed Web of Science ®Google Scholar
• Taipalensuu J., Tornblom H., Lindberg G., Einarsson C., Sjoqvist F., Melhus H., Garberg P., Sjostrom B., Lundgren B., Artursson P. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 2001; 299: 164–170
   PubMed Web of Science ®Google Scholar
• Takeda M., Babu E., Narikawa S., Endou H. Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur. J. Pharmacol. 2002; 438: 137–142
   PubMed Web of Science ®Google Scholar
• Tanigawara Y., Okamura N., Hirai M., Yasuhara M., Ueda K., Kioka N., Komano T., Hori R. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J. Pharmacol. Exp. Ther. 1992; 263: 840–845
   PubMed Web of Science ®Google Scholar
• Tian X., Zamek-Gliszczynski M. J., Zhang P., Brouwer K. L. Modulation of multidrug resistance-associated protein 2 (Mrp2) and Mrp3 expression and function with small interfering RNA in sandwich-cultured rat hepatocytes. Mol. Pharmacol. 2004; 66: 1004–1010
   PubMed Web of Science ®Google Scholar
• Treiber A., Schneiter R., Delahaye S., Clozel M. Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J. Pharmacol. Exp. Ther. 2004; 308: 1121–1129
   PubMed Web of Science ®Google Scholar
• Troutman M. D., Thakker D. R. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm. Res. 2003; 20: 1200–1209
   PubMed Web of Science ®Google Scholar
• Tsujimoto M., Hirata S., Dan Y., Ohtani H., Sawada Y. Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects. Drug Metab. Pharmacokinet. 2006; 165–169
   Google Scholar
• Wang D. S., Jonker J. W., Kato Y., Kusuhara H., Schinkel A. H., Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J. Pharmacol. Exp. Ther. 2002; 302: 510–515
   PubMed Web of Science ®Google Scholar
• Wang J. S., Ruan Y., Taylor R. M., Donovan J. L., Markowitz J. S., DeVane C. L. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int. J. Neuropsychopharmacol. 2004; 7: 415–419
   PubMed Web of Science ®Google Scholar
• Wong H., Lehman-McKeeman L. D., Grubb M. F., Grossman S. J., Bhaskaran V. M., Solon E. G., Shen H. S., Gerson R. J., Car B. D., Zhao B., Gemzik B. Increased hepatobiliary clearance of unconjugated thyroxine determines DMP 904-induced alterations in thyroid hormone homeostasis in rats. Toxicol. Sci. 2005; 84: 232–242
   PubMed Web of Science ®Google Scholar
• Yamazaki M., Akiyama S., Nishigaki R., Sugiyama Y. Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharm. Res. 1996; 13: 1559–1564
   PubMed Web of Science ®Google Scholar
• Yanase K., Tsukahara S., Asada S., Ishikawa E., Imai Y., Sugimoto Y. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol. Cancer Ther. 2004; 3: 1119–1125
   PubMed Web of Science ®Google Scholar
• Yonezawa A., Masuda S., Yokoo S., Katsura T., Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1–3 and multidrug and toxin extrusion family). J. Pharmacol. Exp. Ther. 2006; 319: 879–886
   PubMed Web of Science ®Google Scholar
• Zeng H., Bain L. J., Belinsky M. G., Kruh G. D. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res. 1999; 59: 5964–5967
   PubMed Web of Science ®Google Scholar
• Zeng H., Liu G., Rea P. A., Kruh G. D. Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res. 2000; 60: 4779–4784
   PubMed Web of Science ®Google Scholar